ORMP
Oramed Pharmaceuticals Inc
NASDAQ: ORMP · HEALTHCARE · BIOTECHNOLOGY
$3.88
+1.04% today
Updated 2026-04-30
Market cap
$163.00M
P/E ratio
2.69
P/S ratio
81.50x
EPS (TTM)
$1.50
Dividend yield
—
52W range
$2 – $4
Volume
0.1M
WallStSmart proprietary scores
50
out of 100
Grade: C
Hold
Investment rating
4.7
Growth
C5.0
Quality
C+6.0
Profitability
B8.3
Valuation
A—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$6.25
+61.08%
12-Month target
$4.14
+6.70%
Intrinsic (DCF)
$22.93
Margin of safety
+85.83%
Price chart
X-Ray snapshot
Strengths
+ Profit margin 3,202.00% — above average
+ ROE 37.10% — strong efficiency
+ 85.83% below intrinsic value
Risks
- Negative free cash flow $-4.05M
- Revenue declining -100.00% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $2.70M | $1.34M | $0.00 | $2.00M | $2.00M |
| Net income | $-37.76M | $5.53M | $-19.10M | $75.32M | $21.28M |
| EPS | — | — | — | — | $1.50 |
| Free cash flow | $-29.20M | $-10.55M | $-8.43M | $-9.15M | $-4.05M |
| Profit margin | -1,397.11% | 412.31% | — | 3,766.20% | 3,202.00% |
Peer comparison
Smart narrative
Oramed Pharmaceuticals Inc trades at $3.88. representing a P/E of 2.69x trailing earnings. Our Smart Value Score of 50/100 indicates the stock is fair. TTM revenue stands at $2.00M. with profit margins at 3,202.00%. Our DCF model estimates intrinsic value at $22.93.
Frequently asked questions
What is Oramed Pharmaceuticals Inc's stock price?
Oramed Pharmaceuticals Inc (ORMP) trades at $3.88.
Is Oramed Pharmaceuticals Inc overvalued?
Smart Value Score 50/100 (Grade C, Hold). DCF value $22.93.
What is the price target of Oramed Pharmaceuticals Inc (ORMP)?
The analyst target price is $6.25, representing +61.1% upside from the current price of $3.88.
What is the intrinsic value of Oramed Pharmaceuticals Inc (ORMP)?
Based on our DCF model, intrinsic value is $22.93, a +85.8% margin of safety versus $3.88.
What is Oramed Pharmaceuticals Inc's revenue?
TTM revenue is $2.00M.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio81.50x
ROE37.10%
Beta1.25
50D MA$3.51
200D MA$2.83
Shares out0.04B
Float0.03B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—